chronic kidney disease
Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn
June 25, 2025Research and Development CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution
Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former …
FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment
September 25, 2023Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …
NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus
May 18, 2023Medical Communications Kapruvia, NICE, Nephrology, chronic kidney disease, pruritus
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National Institute for Health and Care …
Bayer’s cardiovascular drug shows impressive Phase III results
May 11, 2021Manufacturing and Production Bayer, chronic kidney disease, pharma, pharma news, type 2 diabetes
Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events in patients with chronic kidney …
Evotec and Chinook to partner on new kidney disease treatments
March 1, 2021Sales and Marketing CKD, Chinook, Evotec, chronic kidney disease, kidney disease
Evotec and Chinook Therapeutics have agreed a deal to discover and develop new therapies for patients with chronic kidney diseases …
Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease
April 16, 2019Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma
Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …
China becomes first country to approve roxadustat in chronic kidney disease
December 19, 2018Research and Development, Sales and Marketing AstraZeneca, China, chronic kidney disease, pharma
AstraZeneca has announced that its partner Fibrogen has secured the first national approval for its hypoxia-inducible factor prolyl hydroxylase inhibitor …
Astellas’ chronic kidney drug shows superiority at Phase 3
September 20, 2018Research and Development Astellas, chronic kidney disease, pharma, roxadustat
Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with …
Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment
March 30, 2016Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III
Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
